CL2020001290A1 - Método para el tratamiento de enfermedades gastrointestinales con tradipitant. - Google Patents

Método para el tratamiento de enfermedades gastrointestinales con tradipitant.

Info

Publication number
CL2020001290A1
CL2020001290A1 CL2020001290A CL2020001290A CL2020001290A1 CL 2020001290 A1 CL2020001290 A1 CL 2020001290A1 CL 2020001290 A CL2020001290 A CL 2020001290A CL 2020001290 A CL2020001290 A CL 2020001290A CL 2020001290 A1 CL2020001290 A1 CL 2020001290A1
Authority
CL
Chile
Prior art keywords
tradipitant
treatment
gastrointestinal diseases
gastric motility
receptor antagonist
Prior art date
Application number
CL2020001290A
Other languages
English (en)
Inventor
Gunther Birznieks
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2020001290A1 publication Critical patent/CL2020001290A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UN MÉTODO PARA TRATAR TRASTORNOS DE MOTILIDAD GÁSTRICA Y PARA MEJORAR LA MOTILIDAD GÁSTRICA, QUE COMPRENDE EL TRATAMIENTO CON EL ANTAGONISTA DEL RECEPTOR NK-1, TRADIPITANT.
CL2020001290A 2017-11-17 2020-05-15 Método para el tratamiento de enfermedades gastrointestinales con tradipitant. CL2020001290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
CL2020001290A1 true CL2020001290A1 (es) 2020-11-13

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001290A CL2020001290A1 (es) 2017-11-17 2020-05-15 Método para el tratamiento de enfermedades gastrointestinales con tradipitant.

Country Status (13)

Country Link
US (4) US20200030307A1 (es)
EP (1) EP3710000A1 (es)
JP (1) JP7306614B2 (es)
KR (1) KR20200088346A (es)
CN (1) CN111343981A (es)
AU (1) AU2018367623B2 (es)
BR (1) BR112020009520A2 (es)
CA (1) CA3081582A1 (es)
CL (1) CL2020001290A1 (es)
IL (1) IL274541B2 (es)
MX (1) MX2020005167A (es)
NZ (1) NZ764107A (es)
WO (1) WO2019099883A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218636A (zh) * 2018-06-08 2021-01-12 万达制药公司 使用川地匹坦进行治疗的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
KR20210067980A (ko) * 2018-09-28 2021-06-08 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20230145932A1 (en) 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
EP4395778A1 (en) 2021-08-31 2024-07-10 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141559A (en) 2002-04-26 2010-05-14 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists
WO2005042515A1 (en) * 2003-10-24 2005-05-12 Eli Lilly And Company Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2008079600A1 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP5890780B2 (ja) * 2009-11-18 2016-03-22 ヘルシン ヘルスケア ソシエテ アノニム 中枢を介する悪心および嘔吐を治療するための組成物および方法
US10463655B2 (en) * 2015-03-04 2019-11-05 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2017112792A1 (en) * 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
US20230390269A1 (en) 2023-12-07
BR112020009520A2 (pt) 2020-11-03
CA3081582A1 (en) 2019-05-23
WO2019099883A1 (en) 2019-05-23
US20210330656A1 (en) 2021-10-28
CN111343981A (zh) 2020-06-26
MX2020005167A (es) 2020-08-20
JP2021503480A (ja) 2021-02-12
NZ764107A (en) 2024-07-05
US20210093621A1 (en) 2021-04-01
IL274541B1 (en) 2024-06-01
KR20200088346A (ko) 2020-07-22
RU2020119259A (ru) 2021-12-17
IL274541A (en) 2020-06-30
JP7306614B2 (ja) 2023-07-11
IL274541B2 (en) 2024-10-01
EP3710000A1 (en) 2020-09-23
AU2018367623A1 (en) 2020-05-21
AU2018367623B2 (en) 2024-03-28
US20200030307A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
PH12019500095A1 (en) Compounds, compositions, and methods for the treatment of disease
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
TW201713333A (en) Methods of treating a neurodegenerative disease
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
CL2020000655A1 (es) Tratamiento mejorado de dermatitis atópica con tradipitant.
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
CL2020002165A1 (es) Uso de tradipitant para tratar la cinetosis.
CU24618B1 (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)